The Wnt family of secreted glycoproteins is widely involved in cell proliferation, differentiation and oncogenesis. Many Wnt signaling genes are upregulated and activated in chronic lymphocytic leukemia. Less is known concerning acute leukemia. One subtype of acute lymphoblastoid leukemia (ALL) is characterized by a t(1;19) chromosomal translocation resulting in a fusion protein E2A-Pbx1 that promotes transformation and leukemogenesis. Wnt16 has been shown to be targeted by E2A-Pbx1. We performed a differential gene expression array in acute leukemia cell lines displaying or not displaying the t(1;19) translocation. We found that Wnt16 and many Wnt signaling-related genes were upregulated in the translocation-containing cells. As two isoforms of Wnt16, Wnt16a and Wnt16b, have been recently identified, we demonstrated by using RT-PCR and Western blot that Wnt16b (and not Wnt16a) is overexpressed in t(1;19)-containing cell lines. We then directly addressed the role played by both isoforms in this type of leukemia. Using specific short interfering RNA (siRNA) and an antiWnt16 antibody, we showed that targeted-Wnt16b inhibition leads to apoptotic cell death. We also demonstrated that Wnt16b mediates its effect through the canonical Wnt pathway involving dishevelled-2, b-catenin and survivin. We thus propose that Wnt16 plays an important role in leukemogenesis, raising its therapeutic interest.
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The Wnt family of secreted glycoproteins is a group of signaling molecules that is widely involved in developmental processes and oncogenesis. Currently, 19 human Wnt proteins have been identified. The proto-oncogenic effects of Wnt were discovered more than 20 years ago (Nusse and Varmus, 1982) and since then numerous reports have demonstrated aberrant activation of the Wnt signaling pathway in disparate human cancers (Morin et al., 1997; Rhee et al., 2002; Weeraratna et al., 2002) . We reported the overexpression of dishevelled (Dvl) proteins in thoracic malignancies (Uematsu et al., 2003a, b) . It is also known that Wnt proteins regulate early B-cell growth and survival (Reya et al., 2003) and the activation of the Wnt signaling pathway has been demonstrated in chronic lymphocytic leukemia (Lu et al., 2004) .
Another area of interest regarding the Wnt proteins is the acute leukemias that are often characterized by translocations that can determine prognosis and treatment options. Muller-Tidow et al. (2004) reported that translocations in acute myeloid leukemia could activate the Wnt signaling pathway. Among these chromosomal abnormalities, the t(1;19) translocation results in the production of chimeric E2A-Pbx1 proteins that display oncogenic properties (Kamps et al., 1991) . The molecular properties of E2A-Pbx1 have been extensively characterized and several candidate target genes have been identified. Light has been shed on Wnt16 in recent studies. Representational differential expression analysis performed in leukemia cell lines containing the fusion protein vs others lacking E2A-Pbx1 identified Wnt16 as a putative target gene (McWhirter et al., 1999) . Moreover, gene expression profiling of leukemic blasts showed a marked overexpression of Wnt16 in E2A-Pbx1-expressing leukemias . Nevertheless, the specific role played by Wnt16 and the Wnt-related proteins in acute leukemia has never been addressed so far. Moreover, Fear et al. identified two isoforms of Wnt16, Wnt16a and Wnt16b, and the respective role of each isoform in oncogenesis has also yet to be elucidated.
In order to analyse the Wnt signaling pathway activation, we first performed gene expression profiling using a custom array designed to profile the expression of the Wnt signaling pathway-related genes (GEArray Q Human Wnt Signaling Pathway Gene Array, SuperArray). Four acute lymphoblastic leukemia cell lines were analysed, two containing the t(1;19) translocation (697 and RCH-ACV) and two without the translocation (CCL-119 and NALM-6). We first confirmed the Wnt16 overexpression in both 697 and RCH-ACV cell lines, whereas no signal was seen in the control cell lines.
Moreover, many other genes involved in the Wnt canonical pathway, such as b-catenin, Dvl-2 and Tcf-4, were overexpressed, underlining the activation of the Wnt signaling pathway in those cells (Figure 1 ). We should note that other Wnt proteins (Wnt2 and Wnt6) are overexpressed in CCL-119, suggesting that various Wnt proteins may be upregulated in different leukemia subtypes in agreement with the findings of MullerTidow et al. (2004) .
To further confirm the previous data, we analysed Wnt16 expression by both Western blot and RT-PCR. We first demonstrated, by using a commercially available Wnt16 polyclonal antibody (Santacruz Biotechnologies), that Wnt16 is not expressed in both NALM-6 and CCL-119 control cell lines and is highly overexpressed in both 697 and RCH-ACV (Figure 2a) (Figure 2b ), whereas Wnt16a was not detected (data not shown). As Fear et al. suggested that Wnt16a was more likely to be targeted by E2A-Pbx1 than Wnt16b, we confirmed by sequencing analysis that the amplified band corresponded strictly to Wnt16b ( Figure 2c ).
As Wnt16b appeared to be a putative target to mediate the effects of the fusion protein E2A-Pbx1, we thus studied its ability to control apoptosis and cell survival. We designed specific siRNA for Wnt16a and Wnt16b. Four siRNA were used, one nonsilencing siRNA, one siRNA targeting both Wnt-16a and three siRNA targeting specifically Wnt-16b. SiRNAs were purchased from Qiagen (Valencia, CA, USA) and sequences were the following: We followed the protocol proposed by Tuschl et al. (Elbashir et al., 2002 Both of them, 697 and RCH-ACV, contain the t(1;19) translocation, whereas CCL-119 does not and serves as a control. Only the data obtained from CCL-119 and 697 are shown here. After extraction, RNA was subjected to a reverse transcriptase reaction and cDNA probes were labeled with biotin-16-dUTP, and hybridized with the Wnt-specific arrays. Detection was carried out using a chemiluminescent reaction and the membranes were exposed to X-ray film. Wnt16 is surrounded by a black square. The genes that are upregulated in the t(1;19)-containing cell line are surrounded by black circles on the arrays. We first demonstrated by both RT-PCR and Western blot that Wnt16b-specific siRNA inhibited Wnt16b, whereas Wnt16a siRNA and control siRNA had no effect (Figure 3a) . We then assessed apoptosis by staining the cells with annexin-V and propidium iodide (PI) (Apotarget, BioSource International). Flow cytometry analysis (FACScan, Decton Dickinson) revealed that Wnt16b-specific siRNA induced apoptosis and cell death compared to control. We used three different Wnt16b siRNA and obtained similar results in various experiments. All Wnt16b-specific siRNAs led to a minimal of 35% apoptosis induction (Figure 3b ). Wnt16a siRNA had no effect on cell survival in the cell lines tested (data not shown). We then tested if coexpression of Wnt16b cDNA can rescue the cells from the siRNA antibody-induced apoptosis. We obtained the Wnt16 pcDNA3 plasmid from Dr Yingzi Yang at the NHGRI/NIH. This Wnt16 cDNA is unable to bind to the Wnt16 siRNA we are using that is specially designed to bind the 3 0 -UTR region of Wnt16 mRNA; therefore, can only knock down endogeneous Wnt16. We demonstrated that re-expression of Wnt16 can rescue the cells from the siRNA antibody-induced apoptosis (Figure 3b ).
In the canonical Wnt pathway, Wnt proteins bind to frizzled receptors, activate Dvl proteins, which inhibits the ability of glycogen synthase kinase-3b to phosphorylate b-catenin that can in turn enter the cell nucleus, and activate target genes. We thus analysed the expression of the Wnt pathway's downstream effectors. Western blot analysis was performed on the three cell lines using commercially available antibodies (b-actin, SantaCruz Biotechnologies; b-catenin, Pharmingen; Dvl-2, SantaCruz Biotechnologies; Survivin, SantaCruz Biotechnologies). We showed that Wnt16b inhibition led to a decrease in b-catenin, Dvl-2 and survivin expression in t(1;19)-containing cell lines, whereas no effect was observed on the control cell lines (Figure 3c ). To further confirm our findings, we also performed a Wnt signaling specific microarray as previously described in CCL-119 and 697 cell lines treated with either control (nonsilencing) siRNA or Wnt16b siRNA. We first confirmed the specific inhibition of Wnt16 and showed that this inhibition led also to the downregulation of key components of the Wnt pathway, such as Dvl-2, Tcf-4 and p300 and c-myc (Figure 3d ).
To further confirm and extend our above findings, we used a commercially available anti-Wnt16 antibody (BD pharmingen). Apoptotic assay was performed 3-4 days afterwards. Anti-Wnt16 antibody induced apoptosis in RCH-ACV cell line, whereas no effect was noticed in the control cell line (Figure 4) . We then analysed if reexpression of Wnt16b can rescue the cells from the monoclonal antibody-induced apoptosis. We demonstrated that re-expression of Wnt16 can rescue the cells from the monoclonal antibody-induced apoptosis (Figure 4 ).
The t(1;19) chromosomal translocation results in the production of a fusion production E2A-Pbx1. The activated oncoprotein E2A-Pbx1 induces transformation in several cell types in vitro and induces lymphoblastic lymphomas in transgenic mice (Kamps et al., 1991) . Recently, expression profiles obtained using microarrays identified t(1;19) (E2A-Pbx1) as one of the six prognostic subtypes of pediatric ALL (Yeoh et al., 2002) . E2A-Pbx1 is known to induce tumour formation in nude mice (Kamps et al., 1991) and to promote myeloid leukemias (Kamps et al., 1996) . The mechanisms by which E2A-Pbx1 produces pre-B-cell ALL still remain unclear (Aspland et al., 2001) . We propose that Wnt16b is of paramount importance in this subtype of leukemia. The specific function of Wnt16 was first addressed by McWhirter et al. (1999) , who proposed that Wnt16 might contribute to the development of t(1;19) pre-B ALL. Using custom diagnostic microarrays, Ross et al. (2003) reported significant overexpression of Wnt16 ranging from a 569-to 2547-fold change when comparing the mean signal value in Proteins from all three cell lines were extracted and an equal amount (20-30 mg/lane) was subjected to immunoelectrophoresis and probed with a commercially available polyclonal antibody against Wnt16. Membranes were reprobed with an anti-b-actin antibody as a control. (c) We confirmed by sequence analysis that the amplified band corresponds strictly to Wnt16b. We show here a portion of the first exon of Wnt16b, which is known to be different from the first exon of Wnt16a
Wnt16 in t(1;19)-leukemia J Mazieres et al the E2A-Pbx1-expressing leukemia to other leukemia. Wnt16 is also overexpressed in chronic lymphocytic leukemia (Lu et al., 2004) . Other putative targets for E2a-Pbx1 have been proposed. Fu and Kamps (1997) first analysed genes induced by E2a-Pbx1 in fibroblasts and identified some tissue-specific and developmentally regulated genes. In human t(1;19)-containing pre-B-cell ALL, they reported that EB-1 overexpression could interfere with proliferation (Fu et al., 1999) . Recently, Smith et al. (2003) demonstrated that E2a-Pbx1 induction enhances expression of Bmi-1, a lymphoid oncogene whose product functions as a transcriptional Wnt16a-specific siRNA and 16b: Wnt16b-specific siRNA) and, 3 days afterwards, RNA was extracted, quantified and an RT-PCR was performed using the same primers as previously described. Actin serves as a control. The same cells were also transfected according to the same procedure. Proteins were extracted 3 days after the transfection and Western blot was performed with an antiWnt16 polyclonal antibody. (b) Cells were transfected by control siRNA (white), Wnt16b siRNA þ empty vector (grey) and Wnt16b siRNA þ Wnt16b cDNA (black), and 3 days later were subjected to an apoptotic assay by flow cytometry as described in Materials and methods. The mean value of apoptotic cell rate was calculated from three independent experiments. The bar graph shows the average of apoptotic rate and error bars are s. Based on microarray data, Downing also proposed CMer as testable potential target due to its overexpression and its ability to cause transformation (Carroll et al., 2003) . The respective role of these putative target genes and their likely interactions remain largely unknown and warrant further investigations in order to define which one(s) could represent a relevant clinical target. The data here demonstrate, for the first time, an important function of Wnt16 in leukemogenesis. Here, we used two different techniques to inhibit Wnt16, RNA small interference and antibody. Both approaches led to the same observations: inhibition of Wnt16 induces apoptosis through the canonical Wnt pathway. We can thus hypothesize that aberrant Wnt signaling mediated by Wnt16 contributes to the failing in apoptosis that is the signature of this highly aggressive malignancy. Our results added to other reports (Reya et al., 2000; MullerTidow et al., 2004; Lu et al., 2004) , raise the importance of Wnt signaling in oncogenesis and extend our previous findings in solid tumours to hematopoietic malignancies. We provide new insights into the role played by Wnt16 in this subset of leukemia displaying the t(1;19) translocation. Our findings raise the therapeutic interest of targeting Wnt16 in this disease.
